SCHEMBL13610959

SCHEMBL13610959

CNc1cc(C(=O)NC[C@@H]2CCN(C(=O)OC(C)(C)C)CC2O)c2c(c1C)OCCO2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
EED O75530 2/20 0.38
RBBP4 Q09028 2/20 0.38
SUZ12 Q15022 2/20 0.38
EZH2 Q15910 2/20 0.38
AEBP2 Q6ZN18 2/20 0.38
GNRHR P30968 1/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
IL1B P01584 1/20 0.35
P2RX7 Q99572 1/20 0.35
ACKR3 P25106 1/20 0.35
MAPT P10636 2/20 0.35
PDGFRB P09619 1/20 0.35
KDR P35968 1/20 0.35
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
TP53 P04637 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13603091 0.91 KDM4E (0.39) KDM4EPKMEEDRBBP4SUZ12
SCHEMBL13603095 0.84 KDM4E (0.41) KDM4EPKMEEDRBBP4SUZ12
SCHEMBL13603084 0.83 KDM4E (0.39) KDM4EPKMMEN1KMT2AIL1B
SCHEMBL13603086 0.83 KDM4E (0.39) KDM4EPKMEEDRBBP4SUZ12
SCHEMBL13610711 0.83 KDM4E (0.39) KDM4EPKMMEN1KMT2AIL1B
SCHEMBL13610955 0.83 KDM4E (0.39) KDM4EPKMEEDRBBP4SUZ12
SCHEMBL13607540 0.82 IL1B (0.39) KDM4EPKMMEN1KMT2AIL1B
SCHEMBL13600588 0.82 IL1B (0.39) KDM4EPKMMEN1KMT2AIL1B
SCHEMBL13607394 0.81 IL1B (0.40) KDM4EPKMEEDRBBP4SUZ12
SCHEMBL13610960 0.81 KDM4E (0.39) KDM4EPKMEEDRBBP4SUZ12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638535-B2 (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity JANSSEN PHARMACEUTICA N.V. (BE) 2009-12-29 US disclosed